navigation navigation
navigation

News

21 Nov 2018

Talgo awarded 2018 Internationalization Award

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

28 Sep 2018

YM&U joins forces with Trilantic Europe following rebrand

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

24 Jul 2018

Gamenet Group signed the agreement for the acquisition of 100% of GoldBet

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

15 Dec 2017

Trilantic Europe invests in the Oberberg Group

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

6 Dec 2017

Gamenet Group completed the listing on Borsa Italiana

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

4 Dec 2017

Elisabetta Franchi purchases 25% of Betty Blue S.p.A. from Trilantic Europe

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

2 Nov 2017

Talgo shortlisted for HS2 rolling stock procurement

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

1 Jun 2017

Trilantic Europe invests in leading bioethanol business in Spain and France

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

7 Apr 2017

Trilantic Europe becomes a shareholder in Pacha Group

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

28 Nov 2016

Talgo wins the most important high-speed tender in Europe with its new Avril, the most advanced high-speed train

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

24 Feb 2016

Trilantic Europe Invests In Maugeri, Leading Italian Non-Acute Private Hospital Operator

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

13 Oct 2015

Trilantic Europe completes acquisition of 90% stake in leading Italian pharmaceuticals producer Doppel Farmaceutici

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

1 Jul 2015

Trilantic Europe raises €900 million

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

1 Jul 2015

IPO of Trilantic Europe IV’s portfolio companies, Talgo and Euskaltel

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

26 Mar 2015

Prettl and Trilantic Europe announce a partnership agreement

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

14 Jan 2015

Trilantic Capital Partners has realised its investment in Clarion Events

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

17 Oct 2013

Trilantic acquires stake in Elisabetta Franchi

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

16 Sep 2013

Gamenet successfully issues €200mn in its debut bond offering

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

26 Jun 2013

Spain's Talgo Awarded €482 million Contract In Kazakhstan

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

20 Nov 2012

Trilantic Europe exits Istanbul Doors Group, owner of the leading restaurants in Istanbul and Tom Aiken’s restaurants in London

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

14 May 2012

Marex Spectron to acquire Schneider Trading Associates Pro-Trader Division

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

12 Dec 2011

Talgo manufacturing facility opens in Kazakhstan

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

26 Oct 2011

Talgo awarded the High-Speed Mecca-Medina mega-contract

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

12 Apr 2011

Michel Léonard joins Trilantic Capital Partners as operating partner

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

24 Mar 2011

The Istanbul Doors Restaurant Group Acquires the Restaurant Business of Michelin-Starred Chef Tom Aikens

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

22 Mar 2011

Marex Group Reaches Agreement to Acquire Spectron Group

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

14 Feb 2011

Appointment of John Danilovich to Trilantic European Advisory Council

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

17 Jan 2011

Refresco Group Announces its Intention to Acquire Spumador

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

14 Jan 2011

Trilantic Capital Partners commits up to €50 million in LeYa

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

7 Jan 2011

Trilantic Capital Partners to Invest €53 million in Gamenet

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

11 Nov 2010

Talgo is awarded the contract to renew and expand the intercity passenger train coaches of the national railway company of Kazakhstan

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

28 Jul 2010

Thai Union Frozen Products Board of Directors Approves Acquisition of MW Brands from Trilantic Capital Partners

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

10 Feb 2010

Trilantic Capital Partners has Successfully Realized its Ownership Stake in Industria de Turbo Propulsores S.A.

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

24 Sep 2009

Talgo: Spanish Minister of Transportation to Support Talgo in its Internationalization

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

17 Jul 2009

Talgo: Governor Doyle Announces Agreement with Talgo to Bring New Trains, Assembly and Maintenance Facilities to Wisconsin

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

16 Jul 2009

Istanbul Doors: Company Receives a Special Award at the Retailer Awards Recently Held in Istanbul

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

9 Apr 2009

Istanbul Doors: Group Launches New Italian Restaurant Concepts

Trilantic Europe, a private equity firm focused on mid-market transactions in Europe, closed today its investment in Oberberg Group (“Oberberg” or the “Company”), a leading operator of psychotherapy, psychiatry and psychosomatic acute clinics in Germany with a focus on treatments for depression and addictions.

The transaction allows Trilantic Europe to invest in a leading and specialised healthcare operator in the German private psychotherapy market based on an attractive portfolio of clinics and a unique therapy concept.

Oberberg Group operates nine clinics at eight locations with approximately 560 beds focused on privately insured patients. The clinics operate under different brands including Oberberg Kliniken, SOMNIA Privatkliniken, Rhein-Jura Klinik and Parkklinik Wiesbaden Schlangenbad. Oberberg differentiates itself through a unique therapy concept based on individual, intensive and innovative treatment delivery. This is accomplished by an experienced group of doctors who are leading experts in their respective fields and a strong patient-to-therapist ratio across the network of clinics.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Oberberg’s unique and leading therapy concept and its attractive position in the German healthcare system. Management has built a strong platform to provide acute psychiatric and psychotherapy treatments in Germany and we are excited to partner with the management team and support their expansion strategy centred on the Oberberg therapy concept.”

Prof. Dr. med. Michael Almeling, Speaker of the Management Board of Oberberg, said: 'We are delighted to announce our partnership with Trilantic Europe and are looking forward to benefit from Trilantic Europe’s experience in healthcare services with regards to implementing our growth strategy. Together, we understand that Oberberg’s leadership with regards to treatment quality and innovative therapy-concepts is an important foundation for future success.”

The transaction represents Trilantic Europe’s fourth investment in the healthcare sector.

Press Enquiries

About Trilantic Europe

Trilantic Europe is a private equity firm focused on control and co-control investments in leading mid-market companies in Western Europe. Trilantic Europe currently manages two institutional private equity funds with aggregate capital commitments of €1.5 billion. In addition to the healthcare sector, Trilantic Europe invests across industries such as consumer & leisure, industrials, TMT and business services.

Contact

Trilantic Europe

London

35 Portman Square, London W1H 6LR, United Kingdom

Guernsey

Le Marchant Street, St Peter Port, Guernsey GY1 4HY

Luxembourg

26 Bd Royal, L-2449 Luxembourg, Luxembourg